Advertisement
Screener

Minerva Neurosciences, Inc. (NERV) Long-Term Debt, Maturity, Year Two

2.8 / 5 stars · 68/120 Roast Me

Minerva Neurosciences, Inc. Long-Term Debt, Maturity, Year Two

Minerva Neurosciences, Inc. (NERV) had Long-Term Debt, Maturity, Year Two of $1.57 million as of 2015-09-30, per its 10-Q filed 2015-11-05.

Discontinued › Notes › Long-Term Debt, Fiscal Year Maturity › Long-Term Debt, Maturity, Year Two and Three

us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo · last filed 2015-11-05

  • 2015-09-30: Long-Term Debt, Maturity, Year Two $1.57M.
  • 2015-06-30: Long-Term Debt, Maturity, Year Two $3.14M.
  • 2015-03-31: Long-Term Debt, Maturity, Year Two $3.14M.
Period endLong-Term Debt, Maturity, Year Two
2015-09-30$1.57M
10-Q · filed 2015-11-05
2015-06-30$3.14M
10-Q · filed 2015-08-05
2015-03-31$3.14M
10-Q · filed 2015-05-07

Similar stocks

Stock NameCountryMarket CapPE Ratio
Tonix Pharmaceuticals Holding Corp. (TNXP)United States$0.166B-1.34
ADC Therapeutics SA (ADCT)$0.163B-1.39
LIFECORE BIOMEDICAL, INC. DE (LFCR)United States$0.163B-8.50
Organogenesis Holdings Inc. (ORGO)United States$0.182B-3.70
Annexon, Inc. (ANNX)United States$0.147B-4.22
AN2 Therapeutics, Inc. (ANTX)United States$0.185B-4.84
PepGen Inc. (PEPG)United States$0.186B-1.73
Corbus Pharmaceuticals Holdings, Inc. (CRBP)United States$0.144B-1.72
ALX ONCOLOGY HOLDINGS INC (ALXO)United States$0.187B-3.52
Fortress Biotech, Inc. (FBIO)United States$0.188B0.91